Singapur - angličtina - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - terazosin hcl - tablet - 1 mg - terazosin hcl 1 mg

Singapur - angličtina - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - terazosin hcl - tablet - 2 mg - terazosin hcl 2 mg

Singapur - angličtina - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - terazosin hcl - tablet - 5 mg - terazosin hcl 5 mg

Jihoafrická republika - angličtina - South African Health Products Regulatory Authority (SAHPRA)

pharmaco distribution (pty) ltd - tablet - see ingredients - each tablet contains granisetron hydrochloride 1 mg granisetron

Jihoafrická republika - angličtina - South African Health Products Regulatory Authority (SAHPRA)

pharmaco distribution (pty) ltd - tablet - see ingredients - each tablet contains granisetron hydrochloride equivalent to granisetron 2,0 mg

Kanada - angličtina - Health Canada

bgp pharma ulc - terazosin hydrochloride - tablet - 5mg - terazosin hydrochloride 5mg - alpha-adrenergic blocking agents

Kanada - angličtina - Health Canada

bgp pharma ulc - terazosin hydrochloride - tablet - 1mg - terazosin hydrochloride 1mg - alpha-adrenergic blocking agents

Kanada - angličtina - Health Canada

bgp pharma ulc - terazosin hydrochloride - tablet - 2mg - terazosin hydrochloride 2mg - alpha-adrenergic blocking agents

Kanada - angličtina - Health Canada

bgp pharma ulc - terazosin hydrochloride - tablet - 10mg - terazosin hydrochloride 10mg - alpha-adrenergic blocking agents

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

viatris limited - terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mg terazosin; terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg terazosin - tablet - active: terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mg terazosin excipient: lactose monohydrate magnesium stearate maize starch purified talc starch active: terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg terazosin excipient: lactose monohydrate magnesium stearate maize starch quinoline yellow starch - the symptomatic and pathophysiologic treatment of benign prostatic hyperplasia (bph) when: -prostatectomy is not indicated -patient is not fit for surgery -elective surgery must be postponed (e.g., waiting list) -patient refuses surgical treatment.